共 40 条
- [21] Adjuvant pembrolizumab versus placebo in resected high- risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyEUROPEAN JOURNAL OF CANCER, 2022, 176 : 207 - 217Khattak, Muhammad A.Luke, Jason J.Long, Georgina V.Ascierto, Paolo A.Rutkowski, PiotrSchadendorf, DirkRobert, CarolineGrob, Jean-JacquesMerino, Luis de la CruzDel Vecchio, MicheleSpagnolo, FrancescoMackiewicz, JacekChiarion-Sileni, VannaCarlino, Matteo S.Mohr, PeterDe Galitiis, FedericaRoss, Merrick I.Eroglu, ZeynepChen, KeJiang, RuixuanFukunaga-Kalabis, MizuhoKrepler, ClemensEggermont, Alexander M. M.Kirkwood, John M.
- [22] Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanomaEUROPEAN JOURNAL OF CANCER, 2021, 158 : 156 - 168Eggermont, Alexander M. M.Meshcheryakov, AndreyAtkinson, VictoriaBlank, Christian U.Mandala, MarioLong, Georgina, VBarrow, CatherineDi Giacomo, Anna MariaFisher, RosalieSandhu, ShahneenKudchadkar, RaginiRomero, Pablo Luis OrtizSvane, Inge MarieLarkin, JamesPuig, SusanaHersey, PeterQuaglino, PietroQueirolo, PaolaStroyakovskiy, DaniilBastholt, LarsMohr, PeterHernberg, MicaelaChiarion-Sileni, VannaStrother, MatthewHauschild, AxelYamazaki, Naoyavan Akkooi, Alexander CjLorigan, PaulKrepler, ClemensIbrahim, NageatteMarreaud, SandrineKicinski, MichalSuciu, StefanRobert, Caroline
- [23] Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trialANNALS OF ONCOLOGY, 2021, 32 : S1314 - S1315Luke, J.Rutkowski, P.Queirolo, P.Del Vecchio, M.Mackiewicz, J.Sileni, V. ChiarionDe la CruzMerino, L.Khattak, M. A.Schadendorf, D.Long, G. V.Ascierto, P. A.Mandala, M.De Galitiis, F.Sondak, V.Scolyer, R. A.Kirkwood, J. M.Chen, K.Ibrahim, N.Ahsan, S.Eggermont, A. M. M.
- [24] Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaEUROPEAN JOURNAL OF CANCER, 2022, 165 : 97 - 112Kennedy, Oliver J.Kicinski, MichalValpione, SaraGandini, SaraSuciu, StefanBlank, Christian U.Long, Georgina, VAtkinson, Victoria G.Dalle, StephaneHaydon, Andrew M.Meshcheryakov, AndreyKhattak, AdnanCarlino, Matteo S.Sandhu, ShahneenLarkin, JamesPuig, SusanaAscierto, Paolo A.Rutkowski, PiotrSchadendorf, DirkKoornstra, RutgerHernandez-Aya, LeonelDi Giacomo, Anna M.van den Eertwegh, Alfonsus J. M.Grob, Jean-JacquesGutzmer, RalfJamal, Rahimavan Akkooi, Alexander C. J.Robert, CarolineEggermont, Alexander M. M.Lorigan, PaulMandala, Mario
- [25] Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Eggermont, Alexander M.Meshcheryakov, AndreyAtkinson, VictoriaBlank, Christian U.Mandala, MarioLong, Georgina V.Barrow, CatherineDi Giacomo, Anna MariaStephens, RosalieSandhu, Shahneen KaurKudchadkar, Ragini ReineyOrtiz-Romero, Pablo L.Svane, Inge MarieVan Akkooi, Alexander Christopher JonathanKrepler, ClemensIbrahim, NageatteMarreaud, SandrineKicinski, MichalSuciu, StefanRobert, Caroline
- [26] Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaEUROPEAN JOURNAL OF CANCER, 2023, 189Kennedy, Oliver JohnKicinski, MichalValpione, SaraGandini, SaraSuciu, StefanBlank, Christian U.Long, Georgina, VAtkinson, Victoria G.Dalle, StephaneHaydon, Andrew M.Meshcheryakov, AndreyKhattak, AdnanCarlino, Matteo S.Sandhu, ShahneenLarkin, JamesPuig, SusanaAscierto, Paolo A.Rutkowski, PiotrSchadendorf, DirkBoers-Sonderen, MaryeDi Giacomo, Anna Mariavan den Eertwegh, Alfonsus J. M.Grob, Jean-JacquesGutzmer, RalfJamal, Rahimavan Akkooi, Alexander C. J.Robert, CarolineEggermont, Alexander M. M.Lorigan, PaulMandala, Mario
- [27] Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in MexicoJOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 346 - 353Wurcel, VictoriaRojas Rojas, MonicaUrrego-Reyes, JuanRivera, Daniela MedranoAcevedo, RobertoJiang, RuixuanJiang, ShanZhang, ShujingCaparros, AlfredoKrepler, ClemensFukunaga-Kalabis, MizuhoYounan, Nadine D.Alexander, DeepakHughes, RobertWeston, Georgie
- [28] Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III MelanomaASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 48 - 48Khattak, A.Robert, C.Blank, C. U.Mandala, M.Long, G. V.Atkinson, V.Dalle, S.Haydon, A.Lichinitser, M.Carlino, M. S.Sandhu, S.Larkin, J.Puig, S.Ascierto, P. A.Rutkowski, P.Schadendorf, D.Lorigan, P.Ibrahim, N.Suciu, S.Eggermont, A. M. M.
- [29] COST-EFFECTIVENESS OF DABRAFENIB AND TRAMETINIB COMPARED TO PEMBROLIZUMAB AS ADJUVANT TREATMENT OF STAGE III HIGH-RISK BRAF V600E MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION: A BRAZILIAN PRIVATE PAYER PERSPECTIVEVALUE IN HEALTH, 2019, 22 : S451 - S451Buehler, A.Kim, H. S. J.Fahham, L.Castilho, G.
- [30] Real-world comparison between 6 weeks versus 3 weeks adjuvant pembrolizumab in high-risk stage IIB-IIID cutaneous malignant melanoma: Experience from an academic cancer centerJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Shah, MananShafi, SabaKendra, Kari LynnVerschraegen, Claire F.Wu, Richard Cheng Han